Table 1.

CMV role in lymphoma development.

Study	Aim of study	Results
Gupta et al. (38)	Seroprevalence SS/MF vs Non-SS/MF	SS/MF 60.4 % (N=53) Non-SS/MF 61.5% (N=26)
Ballanger et al. (39)	Seroprevalence SS, MF& control group	Control group 37% (N=124) MF 66.67% (N=27) SS 42.86% (N=21) p=0.009
	PCR in affected tissue	CMV was not detected in diagnostic biopsies. CMV was detected in two SS skin biopsies realized at an advanced stage
Herne et al. (40)	Seroprevalence SS/MF vs bone marrow donors	Control group 57.3% (N=1322) MF/SS 97.4% (N=116) p<0.05
	Subanalysis with age-matched subgroups	CTCL 93% (N=32) Control group 53.6% (N=1103) p<0.05
Mehravaran et al. (41)	PCR in affected tissue IE1 (active replication)	IE1 detected in 1/25 Non-HL
	Nested-PCR in affected tissue UL138 (latency) Hodgkin and No Hodgkin	UL138 in 5/25 Non-HL and 1/25 HL

SS, Sézary Syndrome; MF, Mycosis Fungoides; CTCL, Cutaneous T-cell lymphoma; HL, Hodgkin lymphoma.